Sartorius | SRT3 - Cash And Equivalent


Sartorius reported EUR230.7M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
Avita Medical AUD 9.14M 1.1M Jun/2026
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 2.25B 340M Sep/2026
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.46B 323M Sep/2026
Revvity USD 1.02B 162.62M Jun/2026
Sartorius EUR 230.7M 60.3M Sep/2026
Tectonic Therapeutic USD 227.07M 9.83M Jun/2026
Viatris USD 886.5M 917.7M Jun/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026